Biologics and Biosimilars

Biologics are medicines made from living cells through highly complex manufacturing processes. A biosimilar product is a biologic product that is approved based on demonstrating that it is highly similar to an FDA‐approved biologic product. Biologics, on the other hand, are much more complex molecules (in fact, they are proteins) created through biological processes in living cells. Indeed, the demand for biologics is growing exponentially due to their ability to bind to specific cells, which means they have fewer side effects than broadly acting drugs. The chemicals traditionally used in cancer therapy, for instance, bind to every fast-dividing cell because this is a hallmark of cancer cells, but this results in observed side effects such as hair loss. Biologics are better at targeting cancerous cells.

  • Biologics as protein therapies
  • Biosimilar labeling
  • Analytical characterization

Related Conference of Biologics and Biosimilars

March 13-14, 2025

2nd International Conference on Drug Discovery and Development

Prague, Czech Republic
April 07-08, 2025

15th World Congress on Chemistry

Vancouver, Canada
May 14-15, 2025

17th International Conference on Clinical Chemistry

Toronto, Canada
June 26-27, 2025

14th World Congress on Chromatography

Paris, France
August 18-19, 2025

14th World Congress on Biopolymers and Biomaterials

Valencia, Spain
September 22-23, 2025

21st European Organic Chemistry Congress

Dubai, UAE
October 27-28, 2025

15th International Chemistry Congress

London, UK
November 06-07, 2025

6th World Expo on Biopolymers and Bioplastics

Dubai, UAE
December 08-09, 2025

5th International Conference on Analytical Chemistry

Rome, Italy

Biologics and Biosimilars Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in